Global Hemophilia Drugs Market was Worth US$ 9875.4 Mn in 2017, Rising Awareness about Hemophilia Disorder to Fuel Demand, says Fortune Business Insights
Request a Sample Copy of the Research Report
As stated in the report, in 2017 North America emerged dominant in the global market. The regional market was valued at US$ 3684.7 Mn in 2017. North America is expected to dominate the market during the forecast period between 2018 and 2025 as well. The growth witnessed is attributable to rising prevalence of hemophilia A & B in nations such as Canada and U.S. Additionally, the key market players in North America are adopting strategies to gain higher share in the market. This in response is expected to increase the demand for hemophilia drug treatment in the region.
Europe also holds a significant share in the market and is expected to witness impressive growth over the forecast period. Rising awareness about rare disorders such as hemophilia is likely to contribute for Europe hemophilia market expansion. Besides this, Asia Pacific is anticipated to grow at a relatively higher CAGR. The growth witnessed is attributable to the approval of novel therapeutics for hemophilia A, by regulatory authorities of Japan and Australia. Additionally, developing nations such as China and India are receiving investments from public and private authorities to improve the healthcare services. This is anticipated to increase the growth rate in the market and fuel demand for hemophilia drugs treatment.
Quick Buy Hemophilia Drugs Market
Hemophilia A to Dominate Owing to its High Prevalence
In terms of disease indication, the hemophilia A segment was leading the global market. The segment accounted for 85% of the global market in 2017. The segment is anticipated to expand during the forecast period as well. The growth witnessed is attributable to increasing incidences of hemophilia A and high cost associated with hemophilia A treatment. Among the hemophilia types, A & B are most commonly found in patients. Additionally, in 2017 Humira received approval from regulatory authority to improve the treatment ability. This in response is likely to propel the growth rate in the market.
Increasing per capita income and rapid innovation in hemophilia drugs are some factors expected to drive the global market during the forecast period. On the flip side, low awareness about the hemophilia disorder and high cost of hemophilia drugs are a few factor anticipated to restrain the global market.
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
The current pandemic of Covid-19 has made a catastrophic impact on the world. Most businesses are shut as a result of the increasing COVID-19 cases. The healthcare industry is facing shortage of medical aid as there are not enough beds to suffice the needs of the increasing number of patients. The world economy is fluctuating as most businesses are at a halt and the ones running from the vicinity of their homes are barely able to manage revenue.
Special reports on various markets affected by the coronavirus pandemic are provided by Fortune Business Insights. These reports will help visualize the current situation and what strategies can be adopted to help the market gain momentum in the coming years.
Takeda Acquired Shire to Strengthen its Market Position
In 2017, Takeda Pharmaceutical Company Limited was leading the global market and is anticipated to lead the market during the forecast period as well. The growth witnessed is attributable to Takeda’s acquisition of Shire Plc. Owing to the acquisitions Takeda owns a diverse product portfolio and it will help the organization to gain a better market position. This is expected to enable growth in the global hemophilia drugs market. Some of the companies operating in the market are Pfizer Inc., CSL Limited, Grifols, S.A., Bioverativ Inc., Octapharma AG, FERRING LÄKEMEDEL AB, and Aptevo Therapeutics.
Have Any Query? Ask Our Experts
Table of Content
Definitions and Assumptions
Epidemiology of coagulation factor deficiency & hemophilia
Recent industry developments such as mergers & acquisitions
Regulatory scenario in key countries
New products launch
Key industry trends
Global Hemophilia Drugs Market Analysis, Insights and Forecast, 2015-2026
Key Findings / Summary
Market Analysis, Insights and Forecast – By Application
Market Analysis, Insights and Forecast – By Type
Market Analysis, Insights and Forecast – By End User
Market Analysis, Insights and Forecast – By Region
Middle East & Africa
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune - 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
LinkedIn | Twitter | Blogs
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Hemophilia Drugs Market was Worth US$ 9875.4 Mn in 2017, Rising Awareness about Hemophilia Disorder to Fuel Demand, says Fortune Business Insights here
News-ID: 2368798 • Views: 145
More Releases from Fortune Business Insight
Global Hospital Architecture Market to Show Remarkable Growth, Bolstered by Risi …
The increasing number of health issues and the need for better medical facilities are anticipated to create lucrative growth opportunities for the global hospital architecture market, finds Fortune Business Insights in their new study. The study is titled, “Hospital Architecture Market: Global Market Analysis, Insights, and Forecasts, 2019 – 2025.” Advanced Hospital Set-up Buildings to Promote Future Market Growth On account of various health issues prevalent around the world, the hospital architecture
Alpha-1 Antitrypsin Deficiency Treatment Market: Increasing Recommendations For …
The rising prevalence of “alpha-1 antitrypsin deficiency” is expected to aid growth of the global alpha-1 antitrypsin deficiency treatment market, says Fortune Business Insights in a report, titled “Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share and Global Trend By Drug Class (Alpha-1 proteinase inhibitor, Bronchodilators, Steroids, Antibiotics), By Route of Administration (Oral, Injection, Inhalation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores) and Geography Forecast till 2026.” The emerging
Sterilization Indicator Tape Market to Hit USD 171.5 Million in 2028; Usage of S …
The global sterilization indicator tape market is set to gain momentum from the rising usage of steam autoclaves for purifying surgical instruments, such as lancets, forceps, and scalpels. The National Center for Biotechnology Information declared that when used for 3-12 hours, chemicals, namely, hydrogen peroxide (7.5%), glutaraldehyde (≥2.4%), and peracetic acid (PAA) (0.2%) can sterilize instruments. As per a report by Fortune Business Insights™, titled, “Sterilization Indicator Tape Market, 2021-2028,”
Over The Counter Drugs Market to Reach USD 233.6 Billion in 2028; Rising Geriatr …
The global OTC drugs market is set to gain momentum from the increasing inclination of manufacturers towards over-the-counter medications from prescription drugs. In 2019, Bayer AG, for instance, mentioned that it is planning to change a few of its prescriptive products that are suitable for self-care to OTC. This information is given by Fortune Business Insights™ in a report, titled, “OTC Drugs Market, 2021-2028.” As per the report, the market
More Releases for Hemophilia
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia Gene Therapy - A Pipeline Analysis Report
"The Report Hemophilia Gene Therapy - A Pipeline Analysis Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Hemophilia Gene Therapy: An insight Hemophilia is an inherited bleeding disorder. The gene responsible for hemophilia is present on the X chromosome and is inherited in a recessive manner. Hemophilia A, also called as factor VIII (FVIII) deficiency or classic hemophilia, is caused by missing
Global Hemophilia Treatment Market to 2024
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions Global hemophilia treatment market was valued at $10.2bn in 2015 and is forecast to grow at a modest 5.4% CAGR between 2015 and 2024, culminating
Hemophilia B Market Pipeline Review, H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include